← all companies · 2026-07-07 · moat: wide · raw .md

ITC: The Locked Room That Prints Cash

One line in the ledger

Every kirana shopkeeper keeps some version of the same ledger, and if you were allowed to read one — say, in a lane off a bus stand in Nagpur — you would find a quiet anomaly. The shop's shelves hold a hundred items: biscuits, soap, batteries, cooking oil. But one line dominates the day's turnover and, more strangely, never needs to be discounted, never goes stale on the shelf, and is asked for by name, by brand, in a mumble, a dozen times an hour: cigarettes. The shopkeeper does not display them proudly — by law he cannot advertise them at all — and yet the small locked showcase near the till is, rupee for rupee of shelf space, the most productive real estate in the shop.

That anomaly is the subject of this chapter. Why does one product sell itself under a legal gag order? The answer lies in a molecule that fits a lock in the human brain, and in the strange economics of an industry that regulation has frozen — competitors locked out, incumbents locked in — around one of the most reliable cash flows in Indian business. The company that owns most of that flow has spent five decades asking itself the question every rich institution eventually faces: what do you do with money you cannot reinvest where you earned it?

A molecule that fits a lock

Nicotine deserves to be understood soberly, because it is one of the most precisely targeted natural compounds known, and everything about this industry follows from its pharmacology.

Your nervous system communicates with chemical messengers, and one of the oldest is acetylcholine — the signal that fires muscles and sharpens attention. Neurons receive it through docking ports called receptors, each shaped to admit its own messenger the way a lock admits a key. Nicotine, a small molecule the tobacco plant evolved as an insecticide, happens by evolutionary accident to fit one family of these ports — the nicotinic acetylcholine receptors, named, in a piece of scientific irony, after the intruder rather than the rightful key.

Three properties of this fit built an industry. First, speed: inhaled in smoke, nicotine crosses from lung to blood to brain in seven to ten seconds — faster than an intravenous injection — and in learning, speed is everything: the brain wires cause to effect most strongly when they arrive nearly together. Second, the target: among the circuits nicotine activates are those that release dopamine in the brain's reinforcement pathways — the machinery that stamps "repeat this" onto behaviour. It is the same machinery that reinforces food and accomplishment; nicotine simply presses the button directly. Third, adaptation: the brain, flooded with a signal, defends itself by dialling its own sensitivity down and changing the receptor population — so the smoker soon needs nicotine not to feel good but to feel normal, and its absence registers as irritability, fog, and craving. Dependence, in other words, is not weak character; it is receptor biology doing exactly what receptor biology does.

This is why the product in the locked showcase behaves like no other consumer good. Demand renews itself chemically, roughly twenty times a day. Brand loyalty is nearly absolute, because the ritual — the specific taste, the throat feel, the pack in the pocket — is welded into the reinforcement loop itself. And demand barely flinches at price, which governments discovered long ago, which is why cigarettes are among the most heavily taxed objects on earth. None of this is a defence of the product; smoking remains the largest preventable cause of death in the world, and this book will not pretend otherwise. But an honest analysis of this company must begin with the honest pharmacology, because the moat is made of it.

The economics of a frozen market

Now watch what regulation — enacted for entirely sound public-health reasons — does to industry structure, because the effect is one of the great unintended lessons in economics.

India banned tobacco advertising, mandated grotesque warnings covering most of the pack, forbade sale to minors, and taxes cigarettes so heavily that the state collects several times more from each pack than the manufacturer earns. The intent is to shrink the market, and legal cigarette volumes have indeed stagnated for years. But consider the side-effects. No advertising means no challenger can build a brand — the weapon by which every incumbent in every other category has ever been overthrown is illegal here. Steep, specific taxes mean scale and pricing discipline decide profitability, entrenching the largest player. High regulatory burden deters any new entrant with a reputation to lose. The market is frozen, and frozen with one company — this one, established in 1910 as the Imperial Tobacco Company of India and Indianised over the following decades — holding the dominant share of legal volumes.

A word on how the company came to be standing in the room when the door was sealed, because the timing was everything. It was founded in Calcutta in 1910 as the Imperial Tobacco Company of India, a colonial outpost of the British tobacco combine, and spent its first decades doing what colonial trading firms did: importing brands, then manufacturing them locally, then — the underrated step — building a leaf-buying operation deep in India's tobacco-growing districts, teaching farmers to cure the crop to cigarette grade. After independence it did what the shrewder colonial companies did: Indianised its shareholding, its management, and eventually its name, becoming a professionally run Indian institution with no promoter at all. By the time India's regulatory freeze descended — the advertising ban arriving in stages through the 1990s and 2000s — the company had spent most of a century building brands, factories, leaf supply, and the relationship with a few million shopkeepers' locked showcases. The freeze then preserved that position the way amber preserves an insect: perfectly, and permanently. A challenger today would need to build all of it — brands it cannot advertise, distribution the incumbents saturate, licences the state has no interest in granting — in order to enter a declining category under a hostile regulator. No one rational will ever try. It is the rare fortress whose walls are manned by its enemies.

The result is a machine with a strange shape: an operating margin that has sat between 34% and 39% for a decade, volumes that barely grow, prices that rise with tax passthroughs, and almost no capital required — the factories were built generations ago. Sales grew from ₹38,817 crore to ₹78,868 crore over ten years, a 7% compound; profit from ₹9,779 crore to ₹21,018 crore, about 8%. (The ₹35,052 crore printed in March 2025 is an accounting spike from the demerger of the hotels business, not earning power — the following year's −40% "decline" is the same illusion reversing.) The right mental model is an annuity: bond-like cash flows secured not by a government's promise but by receptor biology and a regulatory deep-freeze, with the state as a senior partner who takes his cut first and decides the terms annually.

What do you do with a river you cannot dam?

Here the chapter turns from science to the question that has defined this company for fifty years: capital allocation. The cigarette business generates enormous cash — operating cash flow was ₹18,464 crore last year, against ₹9,843 crore a decade ago — and cannot absorb it. You cannot build more cigarette factories for a static market; you cannot advertise; you would not want to double down morally or strategically on a product the century is slowly retiring. So every year the board faces a fork with three tines: return the cash to owners, buy growth elsewhere, or build growth elsewhere.

This company chose, distinctively, to build. Hotels from the 1970s; paperboard and packaging; an agricultural procurement network that reaches millions of farmers (including a genuinely pioneering rural-internet procurement experiment in the early 2000s); and, since the turn of the century, a sprawling consumer-goods construction project — packaged foods, biscuits, noodles, personal care — assembled brand by brand, aiming to convert tobacco's distribution muscle (the company reaches the same kirana showcase every other grocery brand wants) into a second life as an ordinary, respectable FMCG company.

The honest scorecard on that fifty-year project is mixed and improving. The new businesses are real — several of its food brands are now household names — but for decades they consumed capital at returns far below what the cigarette business earned, which is precisely the pattern Munger warned of in institutions: cash-rich managements will build empires because building is more interesting than mailing cheques. The company's own recent behaviour concedes the point: the dividend payout has risen to around 74% of earnings in recent years, and in 2024–25 the hotels — the most capital-hungry and lowest-return of the ventures — were demerged to shareholders rather than fed further. The allocation is migrating, slowly, from empire toward owners.

Munger in the boardroom of a tobacco company

Run the multidisciplinary checks.

Incentives, first and always: the state collects far more per pack than shareholders do, which makes the government — publicly the industry's adversary — privately dependent on its survival. This is the deep stability of the franchise: prohibition is fiscally irrational, so policy settles into perpetual squeezing instead. But note the same incentive's edge: the squeeze ratchets in one direction, and each budget is a renegotiation the company does not attend.

The agency problem of abundance: a management sitting on an unstoppable cash river is tested in a way ordinary managements never are. The absence of a promoter (no controlling family or parent — foreign institutions hold 34.83% and domestic institutions 49.15%) cuts both ways: no controlling shareholder extracts value, but no owner's eye restrains the professional empire-builder either. Owners should read the equity-capital line as a conscience: it grew from ₹802 crore to ₹1,253 crore over the decade — a bonus issue explains the big step, but a steady annual creep of employee stock options explains the rest, a small perpetual toll paid to management that a family-owned rival would not levy.

Inversion — what kills it? Not a competitor; the freeze forbids one. The threats are systemic: a tax rate that finally crosses from squeezing into strangling, pushing volume into the illicit trade (which already thrives — smuggled and untaxed products are the real competitor, and every tax hike is their subsidy); a generational collapse in smoking prevalence, as is underway in rich countries; or category disruption from nicotine-delivery technologies — vaping and heated tobacco — which India has banned outright, a ban that today protects the incumbent and tomorrow may orphan it if the world migrates to products it was never allowed to learn.

The decade's to-dos: first, finish the pivot in capital allocation — the demerger and the fatter dividend are the right direction; the discipline must hold when the next glamorous acquisition presents itself. Second, make the FMCG businesses earn their capital properly: the group's return on capital employed of 38.9% is the cigarette business flattering the average, and the newer businesses must close the gap or shrink. Third, treat the agri network as the strategic asset it is — climate volatility will make reliable procurement scarcer and more valuable. Fourth, prepare, quietly and scientifically, for a post-combustion nicotine world, so that a change in Indian law finds the company holding options rather than nostalgia. Fifth, guard the balance sheet's simplicity: borrowings of ₹2,399 crore against reserves of ₹71,254 crore is the correct posture for a business whose one true risk is political.

The owner's arithmetic

The market values the company at ₹3,61,851 crore — 17.4 times earnings, against the 30s, 50s, and 80s at which India's other consumer franchises trade. The dividend yield is 5.03%. Return on equity is 29.3%. Read those three numbers together and you can hear the market thinking: it is pricing a first-class business as a second-class future — paying annuity prices, not compounding prices, for the highest-margin consumer franchise in the country. The discount is the moral and regulatory shadow, priced in daylight: many global institutions will not own tobacco at any price (the foreign-institutional holding has drifted from 43.62% to 34.83% in under three years while domestic institutions absorbed the difference), and everyone can see that the core product's century is late.

Whether the discount is an opportunity or a verdict depends on a question nobody can answer precisely: how long the frozen room keeps printing. What can be said with confidence is about the business, not the stock: the cash generation is real and demonstrated across every condition a decade can offer; the pricing power is chemical; the competitive position is legally cemented; and the great historical weakness — capital allocation — has visibly improved. The moat is wide. It is also, and owners should say this plainly to themselves, a moat dug around a product that kills its best customers, sustained by a truce between a treasury's needs and a health ministry's aims. Durable, yes. Comfortable, never.

Cracks in the wall

The tax ratchet. Each budget can reset the economics unilaterally. The line between milking and strangling is discovered only by crossing it — and the illicit market waits on the far side.
Prevalence decline. Receptor biology recruits no one by itself; social change is drying the pool of new smokers in urban, educated India, as it did across the rich world.
Technology it is banned from. If reduced-harm nicotine products eventually dominate globally, India's ban — the incumbent's present shield — becomes the incumbent's cage.
Conglomerate temptation. The cash river will outlive the current board's discipline; the institutional imperative is a permanent resident, not a guest.
ESG exclusion. A shrinking pool of permissible owners is a slow, structural de-rating pressure no operating excellence can cure.

The long exhale

Project the structural forces out thirty years and the picture is unusually legible. Indian cigarette volumes will most likely erode slowly — prevalence falling, prices rising, the state extracting its toll to the last — while the cash thrown off funds, if discipline holds, the completion of a second company: foods, personal care, paper, agri, built inside the shell of the first. The investor of 2050 will judge this era's board on a single criterion: whether the tobacco river was piped into assets that earn their keep, or spilled across an empire that did not.

The molecule, for its part, will not change. Nicotine will fit the same receptors in 2050 that it fits tonight in the lane off the bus stand in Nagpur, where the shopkeeper is totalling his ledger and the locked showcase has paid the rent again. The business question was never whether the lock and key would hold. It is what a company becomes while its founding chemistry slowly, profitably, goes out of fashion.

An Omaha Investments chapter. Educational material, not investment advice. Figures from Screener.in and NSE data via Angel One as of the date above.